TY - BOOK AU - Institute of Medicine A2 - Sarah H. Beachy A2 - Samuel G. Johnson A2 - Steve Olson A2 - Adam C. Berger TI - Improving the Efficiency and Effectiveness of Genomic Science Translation: Workshop Summary SN - 978-0-309-29453-9 DO - 10.17226/18549 PY - 2014 UR - https://nap.nationalacademies.org/catalog/18549/improving-the-efficiency-and-effectiveness-of-genomic-science-translation-workshop PB - The National Academies Press CY - Washington, DC LA - English KW - Health and Medicine AB - The process for translating basic science discoveries into clinical applications has historically involved a linear and lengthy progression from initial discovery to preclinical testing, regulatory evaluation and approval, and, finally, use in clinical practice. The low rate of translation from basic science to clinical application has been a source of frustration for many scientists, clinicians, investors, policy makers, and patients who hoped that investments in research would result in improved products and processes for patients. Some feel that the anticipated deliverables from the Human Genome Project have not yet materialized, and although understanding of human health and disease biology has increased, there has not been a concomitant increase in the number of approved drugs for patients over the past 10 years. Improving the Efficiency and Effectiveness of Genomic Science Translation is the summary of a workshop convened by the Institute of Medicine Roundtable on Translating Genomic-Based Research for Health in December 2012 to explore ways to improve the efficiency and effectiveness of the translation of genomic science to clinical practice. The workshop convened academic researchers, industry representatives, policy makers, and patient advocates to explore obstacles to the translation of research findings to clinical practice and to identify opportunities to support improvement of the early stages of the process for translation of genetic discoveries. This report discusses the realignment of academic incentives, the detection of innovative ways to fund translational research, and the generation or identification of alternative models that accurately reflect human biology or disease to provide opportunities to work across sectors to advance the translation of genomic discoveries. ER -